Charles Schwab Investment Management Inc. Buys 11,388 Shares of Cardlytics, Inc. (NASDAQ:CDLX)

Charles Schwab Investment Management Inc. lifted its stake in shares of Cardlytics, Inc. (NASDAQ:CDLX) by 3.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 390,343 shares of the company’s stock after purchasing an additional 11,388 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.77% of Cardlytics worth $1,249,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. GSA Capital Partners LLP boosted its position in Cardlytics by 1,273.2% in the 3rd quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock valued at $1,223,000 after buying an additional 354,474 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Cardlytics by 711.9% during the 2nd quarter. Renaissance Technologies LLC now owns 351,035 shares of the company’s stock worth $2,882,000 after purchasing an additional 307,800 shares during the last quarter. SG Americas Securities LLC acquired a new position in Cardlytics during the 3rd quarter valued at about $45,000. Bank of New York Mellon Corp boosted its stake in shares of Cardlytics by 15.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 135,924 shares of the company’s stock valued at $1,116,000 after purchasing an additional 18,179 shares during the last quarter. Finally, Creative Planning raised its stake in shares of Cardlytics by 35.4% during the third quarter. Creative Planning now owns 29,537 shares of the company’s stock worth $95,000 after buying an additional 7,721 shares during the last quarter. 68.10% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Cardlytics in a report on Thursday, November 7th. Evercore ISI began coverage on Cardlytics in a research note on Friday, October 11th. They issued an “in-line” rating and a $4.00 price target for the company. Finally, Craig Hallum upgraded shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $6.92.

Cardlytics Trading Up 1.9 %

CDLX opened at $3.84 on Wednesday. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40. The stock has a market capitalization of $195.16 million, a P/E ratio of -0.63 and a beta of 1.53. The firm’s fifty day simple moving average is $3.91 and its 200 day simple moving average is $5.34. Cardlytics, Inc. has a 12 month low of $2.89 and a 12 month high of $20.52.

Cardlytics (NASDAQ:CDLX) last released its earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.18. Cardlytics had a negative net margin of 93.55% and a negative return on equity of 110.67%. The business had revenue of $67.06 million during the quarter, compared to the consensus estimate of $57.77 million. During the same quarter last year, the firm earned ($0.26) earnings per share. The firm’s revenue for the quarter was down 15.1% compared to the same quarter last year. As a group, research analysts anticipate that Cardlytics, Inc. will post -1.52 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Alexis Desieno sold 25,118 shares of Cardlytics stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $3.43, for a total value of $86,154.74. Following the transaction, the chief financial officer now directly owns 116,481 shares of the company’s stock, valued at $399,529.83. This trade represents a 17.74 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Amit Gupta sold 22,607 shares of the business’s stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of $3.85, for a total value of $87,036.95. Following the transaction, the chief executive officer now directly owns 178,519 shares of the company’s stock, valued at approximately $687,298.15. The trade was a 11.24 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 68,691 shares of company stock valued at $237,767. 4.40% of the stock is currently owned by corporate insiders.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.